THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenA judge has once again rejected Musk’s multi-billion-dollar Tesla pay package. Now what?
T he Lonely City by Olivia Laing looks at loneliness in its emotional and psychological dimensions, using New York City as a metaphor for isolation. The book is half-memoir, but also delves into the lives of the city’s most compelling artists — Andy Warhol, Edward Hopper and David Wojnarowicz — all of whom used art to explore their own feelings of isolation and the attendant ugliness. Laing emphasises that loneliness is about the emotional distance between people, often exacerbated by modern society’s emphasis on individualism. As grief and isolation became the norm during the pandemic, different people navigated the storm of their emotions in different ways. The COVID-19 pandemic and multiple lockdowns promoted remote work culture and social distancing has scarred people socially in different ways. For Arunima Singhal, 20, the pandemic was one of the darkest times of her life. Her family grappled with a deep wedge of isolation, each member waking up, doing the chores only to go back to sleep. “There seemed to be barely any point reaching out to people because I wasn’t sure what to talk about. I remember it just really felt like I had to push myself to exist.” Many people also find it hard to remember the person that they were prior to the pandemic, which forms the passageway to feelings of guilt, depersonalisation, and detachment. “I finally started to understand Pink Floyd’s Comfortably Numb,” says Singhal, as she laughs. Tanishqa Mathur, 24, talks about how the pandemic felt like it was a whole other world. “Even though my friend and I found different ways to stay in touch (like watching online movies), we couldn’t trust the reality of virtual connections, and since there was no certainty as to when or if the pandemic would end, loneliness held a sort of gravity.” Now, she says, the pandemic changed how she views all of her relationships with her friends and her romantic partners. The absolute physical isolation seems to have hit several people hard. The loss of touch beckoned people to go online and look at peoples’ lives voyeuristically whilst barely making an effort to change their own. Gen Z is also one of the first generations to fully grow up with so much technology at the press of a button, which seems to have acted as a catalyst to enable things to spiral out of control. While grief and isolation became prevalent in COVID era, it’s aftermath still persists in various ways. Though screens have bridged the distances amongst people, it has also left people emotionally drained. “Many people are now connecting online, but these interactions lack the warmth of face-to-face contact, leaving people feeling detached,” says a Mumbai-based psychotherapist, Neha Mehta. Loneliness has come across a public health crisis in the past few years and is often linked with suicide, mental health disorders and substance abuse. Many school and college students are struggling to adjust and reconnect with their peers after two years of online learning. The increasing consumption of social media and digital interactions during the COVID era has left many people, especially the youth feeling a sense of “digital isolation.” WHO estimated that 10% of adolescents and 25% of old people in India are alone. India’s loneliness epidemic is not only a mental health crisis, it has also come across as a societal challenge threatening social connections and bonds among people. madhumitasharma9318@gmail.com treya.sinha@gmail.com Published - November 24, 2024 02:27 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp RedditSports briefs
Late kickoff return TDs by Turpin and Thomas spark the Cowboys as they end their 5-game skidNoneWASHINGTON (AP) — Rep. Jamie Raskin of Maryland announced Monday that he will run to become the top Democrat on the powerful House Judiciary Committee next year, directly challenging fellow Democratic Rep. Jerry Nadler as the party prepares to fight a second Trump administration and an emboldened Republican majority. "House Democrats must stand in the breach to defend the principles and institutions of constitutional democracy," Raskin wrote in a letter to colleagues. “That is our historic assignment now. We dare not fail.” Raskin said in the letter — obtained by The Associated Press — that he decided to run for the post after spending the week consulting with House Democrats and “engaging in serious introspection” about where the party is following their stunning electoral defeat last month that handed Republicans control of Congress and the White House. While currently the top Democrat on the House Oversight Committee, Raskin said that come next year, the Judiciary Committee under his leadership would become "the headquarters of Congressional opposition to authoritarianism" as well as other efforts by President Donald Trump and his allies to thwart the Constitution. Being the face of the resistance against Trump is not new territory for Raskin who spent the last two years on Oversight as the most vocal defender of President Joe Biden and his family as they faced a sprawling Republican investigation — encouraged by Trump — into their various business affairs. Raskin, who is a former constitutional law professor, also helped draft articles of impeachment against the incoming president for his encouragement of the violent mob on Jan. 6, 2021, and led the impeachment prosecution in the Senate. But by throwing his hat in the ring, Raskin is inviting what a bitter intra-party fight with Nadler, who is currently serving his 17th term in Congress and who has held the top spot on Judiciary since 2019. Democrats have over the years rarely broken from the seniority system for committee assignments, no matter how long someone has held a position, making the outcome of the race uncertain. Both men did not respond to requests for comment but Raskin closed his letter by praising Nadler, saying that he made this decision “with respect and boundless admiration” for him. “If I’m lucky enough to be chosen for this responsibility in the 119th Congress, I will turn to Jerry first and throughout for his always wise counsel and political judgment,” Raskin added.
By TOM KRISHER, Associated Press DETROIT (AP) — For a second time, a Delaware judge has nullified a pay package that Tesla had awarded its CEO, Elon Musk, that once was valued at $56 billion. On Monday, Chancellor Kathaleen St. Jude McCormick turned aside a request from Musk’s lawyers to reverse a ruling she announced in January that had thrown out the compensation plan. The judge ruled then that Musk effectively controlled Tesla’s board and had engineered the outsize pay package during sham negotiations . Lawyers for a Tesla shareholder who sued to block the pay package contended that shareholders who had voted for the 10-year plan in 2018 had been given misleading and incomplete information. In their defense, Tesla’s board members asserted that the shareholders who ratified the pay plan a second time in June had done so after receiving full disclosures, thereby curing all the problems the judge had cited in her January ruling. As a result, they argued, Musk deserved the pay package for having raised Tesla’s market value by billions of dollars. McCormick rejected that argument. In her 103-page opinion, she ruled that under Delaware law, Tesla’s lawyers had no grounds to reverse her January ruling “based on evidence they created after trial.” On Monday night, Tesla posted on X, the social media platform owned by Musk, that the company will appeal. The appeal would be filed with the Delaware Supreme Court, the only state appellate court Tesla can pursue. Experts say a ruling would likely come in less than a year. “The ruling, if not overturned, means that judges and plaintiffs’ lawyers run Delaware companies rather than their rightful owners — the shareholders,” Tesla argued. Later, on X, Musk unleashed a blistering attack on the judge, asserting that McCormick is “a radical far left activist cosplaying as a judge.” Legal authorities generally suggest that McCormick’s ruling was sound and followed the law. Charles Elson, founding director of the Weinberg Center for Corporate Governance at the University of Delaware, said that in his view, McCormick was right to rule that after Tesla lost its case in the original trial, it created improper new evidence by asking shareholders to ratify the pay package a second time. Had she allowed such a claim, he said, it would cause a major shift in Delaware’s laws against conflicts of interest given the unusually close relationship between Musk and Tesla’s board. “Delaware protects investors — that’s what she did,” said Elson, who has followed the court for more than three decades. “Just because you’re a ‘superstar CEO’ doesn’t put you in a separate category.” Elson said he thinks investors would be reluctant to put money into Delaware companies if there were exceptions to the law for “special people.” Elson said that in his opinion, the court is likely to uphold McCormick’s ruling. Experts say no. Rulings on state laws are normally left to state courts. Brian Dunn, program director for the Institute of Compensation Studies at Cornell University, said it’s been his experience that Tesla has no choice but to stay in the Delaware courts for this compensation package. The company could try to reconstitute the pay package and seek approval in Texas, where it may expect more friendlier judges. But Dunn, who has spent 40 years as an executive compensation consultant, said it’s likely that some other shareholder would challenge the award in Texas because it’s excessive compared with other CEOs’ pay plans. “If they just want to turn around and deliver him $56 billion, I can’t believe somebody wouldn’t want to litigate it,” Dunn said. “It’s an unconscionable amount of money.” Almost certainly. Tesla stock is trading at 15 times the exercise price of stock options in the current package in Delaware, Morgan Stanley analyst Adam Jonas wrote in a note to investors. Tesla’s share price has doubled in the past six months, Jonas wrote. At Monday’s closing stock price, the Musk package is now worth $101.4 billion, according to Equilar, an executive data firm. And Musk has asked for a subsequent pay package that would give him 25% of Tesla’s voting shares. Musk has said he is uncomfortable moving further into artificial intelligence with the company if he doesn’t have 25% control. He currently holds about 13% of Tesla’s outstanding shares.
Bucharest Referendum/ Nicusor Dan: I don't think political parties can ignore will of 500,000 BucharestersThe South Carolina women's basketball team has been defeated for the first time since March 31, 2023. The No. 1 Gamecocks fell Sunday in Los Angeles as Lauren Betts posted a double-double effort to lead No. 5 UCLA to a 77-62 triumph. The Gamecocks (5-1) suffered their first defeat after 43 consecutive victories, dating back to the loss to Iowa 77-73 in the NCAA Tournament semifinals. South Carolina defeated Iowa last season for the national championship. Betts finished with 11 points, a game-high 14 rebounds, four assists and four blocks to power the Bruins (5-0) to a historic victory. UCLA also got 15 points from Londynn Jones on 5-of-5 shooting from 3-point range, 13 points from Elina Aarnisalo and 11 each from Kiki Rice and Gabriela Jacquez. It's the first time UCLA has beaten South Carolina since 1981. The Bruins lost twice to the Gamecocks in the 2022-23 season, including in the Sweet 16 of the NCAA Tournament. Te-Hina Paopao had 18 points for South Carolina on 4-of-4 3-point shooting, while Tessa Johnson had 14 points. UCLA won the rebounding battle 41-34, marking the second time this season the Gamecocks have been outrebounded. South Carolina also got outscored in the paint 26-18. It's rare that a Dawn Staley-coached team -- units that typically revolve around dominant centers from A'ja Wilson to Aaliyah Boston to Kamilla Cardoso -- gets beat in the paint and on the glass, but with 6-foot-7 Betts, UCLA had the recipe to outmuscle the Gamecocks in those areas of the game. South Carolina never led after UCLA began the game with an 18-5 run, capped off by back-to-back 3-pointers from Jones. The Gamecocks cut the deficit to nine points in the second quarter, but the Bruins responded with a 17-5 run and entered halftime ahead by 21 points. Aarnisalo scored seven points during that run. From there, the Gamecocks never got within single digits of the lead in the second half. It's the first time in 21 tries that UCLA has beaten an AP-ranked No. 1 team. And it's the first time South Carolina lost a true road game since 2021, a streak of 33 games. The schedule doesn't get any easier for South Carolina. While UCLA faces UT Martin next on Friday, the Gamecocks play No. 8 Iowa State on Thursday. --Field Level Media
Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’
Albemarle Corp. stock underperforms Friday when compared to competitorsJimmy Carter: Many evolutions for a centenarian ‘citizen of the world’